OCM
HZNP

Ovata Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ovata Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,700
Closed -$132K – 82
2020
Q3 		$132K Buy
+1,700
New +$117K 0.05% 57

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ovata Capital Management's HZNP Position: Q4 2020 in Review

Ovata Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 1,700 shares — an estimated $132K sold.

Ovata Capital Management first reported a position in HZNP in Q3 2020 and held it in 1 quarter. The position peaked at $132K in Q3 2020. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

  • Ovata Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
  • Ovata Capital Management sold 1,700 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $132K.
  • Ovata Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 1 quarter.
  • Ovata Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $132K in Q3 2020.
  • 497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Ovata Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.